

PRIOR AUTHORIZATION POLICY

- POLICY:** Topical Retinoids – Tazarotene Products Prior Authorization Policy
- Arazlo[™] (tazarotene 0.045% lotion – Bausch Health)
 - Fabior[®] (tazarotene 0.1% foam – Mayne Pharma, generic)
 - Tazorac[®] (tazarotene 0.05% cream, 0.05% gel, 0.1% cream, and 0.1% gel – Allergan, generics to 0.1% cream, 0.05% gel, and 0.1% gel only)

REVIEW DATE: 08/14/2024

OVERVIEW

Tazorac gel is indicated for the following uses:¹

- **Plaque psoriasis**, in patients with up to 20% body surface area involvement (0.05% and 0.1% strengths).
- **Facial acne vulgaris**, in patients with mild to moderate severity (0.1% strength only).

Tazorac cream is indicated for the following uses:²

- **Plaque psoriasis** (0.05% and 0.1% strengths).
- **Acne vulgaris** (0.1% strength only).

Both Arazlo lotion and Fabior foam are indicated for the topical treatment of **acne vulgaris**.^{3,4}

In addition to acne vulgaris and plaque psoriasis, topical tazarotene products have been used to treat other medical skin conditions, such as basal cell carcinoma and congenital ichthyoses.⁵⁻¹³ Topical tazarotene products have also been used to treat cosmetic skin conditions such as wrinkles, premature aging, and treatment of photo-aged or photo-damaged skin.

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of topical tazarotene products. All approvals are provided for the duration noted below.

Prior authorization and prescription benefit coverage are not recommended for cosmetic uses.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of topical tazarotene products is recommended in those who meet one of the following criteria:

FDA-Approved Indications

1. **Acne Vulgaris.** Approve for 1 year.
2. **Plaque Psoriasis.** Approve for 1 year.

08/14/2024

© 2024. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

Other Uses with Supportive Evidence

3. Treatment of Other Non-Cosmetic Conditions. Approve for 1 year.

Note: Examples of other non-cosmetic conditions include: acne keloidalis nuchae, basal cell carcinoma, comedonal acne, cystic acne, cutaneous T-cell lymphoma, ichthyosis (e.g., congenital, lamellar, vulgaris, X-linked), keratoderma blennorrhagicum, keratosis (e.g., keratosis follicularis [Darier's disease], keratosis pilaris), mycosis fungoides, nail psoriasis, oral lichen planus, and warts.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of topical tazarotene products is not recommended in the following situations:

1. Cosmetic Conditions. Cosmetic use is not recommended for coverage as this indication is excluded from coverage in a typical pharmacy benefit.

Note (this is not an all-inclusive list): Examples of cosmetic conditions include actinic purpura, age spots (also called liver spots, solar lentigines, sun spots), melasma/cholasma, milia, mottled hyperpigmentation, mottled hypopigmentation, photo-aged or photo-damaged skin, pokiloderma (of Civatte), premature aging, scarring, sebaceous hyperplasia, seborrheic keratosis, skin laxity, skin roughness, solar elastosis, solar purpura, stretch marks, and wrinkles.

2. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Tazorac® gel 0.05%, 0.1% [prescribing information]. Irvine, CA: Allergan; April 2018.
2. Tazorac® cream 0.05%, 0.1% [prescribing information]. Irvine, CA: Allergan; August 2019.
3. Arazlo™ lotion [prescribing information]. Bridgewater, NJ: Bausch Health US; August 2023.
4. Fabior® foam 0.1% [prescribing information]. Greenville, NC: Mayne Pharma; February 2023.
5. DRUGDEX® System. Thomson Reuters (Healthcare) Inc. Available at: <https://www.micromedexsolutions.com/micromedex2/librarian/>. Accessed on August 12, 2024. Search term: tazarotene.
6. Facts and Comparisons® Online. Wolters Kluwer Health, Inc.; 2024. Available at: <https://fco.factsandcomparisons.com/lco/action/home>. Accessed on August 12, 2024. Search term: tazarotene.
7. Acne Keloidalis Nuchae. Available at: <https://www.skindsight.com/skin-conditions/adult/acne-keloidalis-nuchae>. Accessed on August 12, 2024.
8. Tanghetti E, Dhawan S, Green L, et al. Clinical evidence for the role of a topical anti-inflammatory agent in comedonal acne: findings from a randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in patients with acne vulgaris. *Drugs Dermatol.* 2011;10:783-792.
9. Morin CB, Roberge D, Turchin I, et al. Tazarotene 0.1% cream as monotherapy for early-stage cutaneous T-cell lymphoma. *J Cutan Med Surg.* 2016;20:244-248.
10. Del Rosso J. Treatment of keratosis pilaris with topical tazarotene cream. *Pediatrics.* 2005;52:P74.
11. Wennberg E, Richards PQ, Bain PA, et al. Topical treatments for early-stage mycosis fungoides using grading recommendations assessment, development and evaluation (GRADE) criteria: a systematic review. *JAAD Int.* 2021;3:26-41.
12. Petruzzi M, De Benedittis M, Grassi R, et al. Oral lichen planus: a preliminary clinical study on treatment with tazarotene. *Oral Dis.* 2002;8:291-295.
13. Petruzzi M, Lucchese A, Lajolo C, et al. Topical retinoids in oral lichen planus treatment: an overview. *Dermatol.* 2013;226:61-67.
14. Pasch N. Nail psoriasis: a review of treatment options. *Drugs.* 2016;76(6):675-705.
15. Rosen T. A multimodality approach to recalcitrant warts. Available at https://assets.bmctoday.net/practicaldermatology/pdfs/PD0812_SF_Warts.pdf. Accessed on August 12, 2024.

